6 completed, 1 active not recruiting, 1 not yet recruiting. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Cabergoline: new trials by email Literature Review of Cabergoline trials Research Report on Cabergoline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline Viaca, Sildenafil 50 mg, Cabergoline 0.5 MG - Erectile Dysfunctions, Healthy Volunteer | Phase 1 | Not yet recruiting | Yanping Kong | 30 | 2026-08-01 | 2026-07-28 |
| A Study on Bioequivalence of Cabergoline Tablets in Human Body Cabergoline tablets test formulation, Cabergoline tablets reference formulation - Hyperprolactinemia | Phase 1 | Active not recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 72 | 2025-06-30 | 2025-11-17 |
| Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia. cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education, cabergoline 1.5-2 mg/week).orally daily for 1 month without health education - Health Education | Phase 1 | Completed | Woman's Health University Hospital, Egypt | 120 | 2020-02-01 | 2023-05-25 |
| A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence Placebo, Cabergoline - Cocaine Dependence, Cocaine Abuse | Phase 1 | Completed | Baylor College of Medicine | 11 | 2011-07-01 | 2012-07-27 |
| Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program Cabergoline, Control - Ovarian Hyperstimulation Syndrome | Phase 1 / Phase 2 | Completed | Royan Institute | 10 | 2009-06-01 | 2015-05-06 |
| Effect of Cabergoline on Weight and Glucose Tolerance Cabergoline, placebo - Body Weight, Impaired Glucose Tolerance in Obese | Phase 1 / Phase 2 | Completed | Columbia University | 40 | 2002-04-01 | 2015-10-14 |
| Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions Cabergoline, Dostinex - To Determine Bioequivalence Under Fasting Conditions | Phase 1 | Completed | Par Pharmaceutical, Inc. | 40 | 2001-08-01 | 2008-04-04 |
| Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions Cabergoline, Dostinex - To Determine Bioequivalence Under Fed Conditions | Phase 1 | Completed | Par Pharmaceutical, Inc. | 24 | 2001-07-01 | 2017-09-26 |
Hyperprolactinemia (2) · Body Weight (1) · Cocaine-Related Disorders (1) · Erectile Dysfunction (1) · Fasting (1) · Health Education (1) · Lecithin Cholesterol Acyltransferase Deficiency (1) · Ovarian Hyperstimulation Syndrome (1) · Substance-Related Disorders (1)
Par Pharmaceutical, Inc. (2) · Baylor College of Medicine (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Columbia University (1) · Royan Institute (1) · Woman's Health University Hospital, Egypt (1) · Yanping Kong (1)
Canada (2) · United States (2) · Australia (1) · China (1) · Egypt (1) · Iran (1)
Eric Masson, Pharm.D. (2) · Ashraf Moini, MD (1) · Atef M Darwish, Prof (1) · Emma Trowbridge, MD (1) · Eniseh Tehraninejad, MD (1) · Judith Korner, MD, PHD (1) · Marzieh Shiva, MD (1)